BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 15975961)

  • 1. Hormesis and dose-response-mediated mechanisms in carcinogenesis: evidence for a threshold in carcinogenicity of non-genotoxic carcinogens.
    Fukushima S; Kinoshita A; Puatanachokchai R; Kushida M; Wanibuchi H; Morimura K
    Carcinogenesis; 2005 Nov; 26(11):1835-45. PubMed ID: 15975961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo Comet assay on isolated kidney cells to distinguish genotoxic carcinogens from epigenetic carcinogens or cytotoxic compounds.
    Nesslany F; Zennouche N; Simar-Meintières S; Talahari I; Nkili-Mboui EN; Marzin D
    Mutat Res; 2007 Jun; 630(1-2):28-41. PubMed ID: 17507283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective.
    Bolt HM; Foth H; Hengstler JG; Degen GH
    Toxicol Lett; 2004 Jun; 151(1):29-41. PubMed ID: 15177638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress in the carcinogenicity of chemical carcinogens.
    Kakehashi A; Wei M; Fukushima S; Wanibuchi H
    Cancers (Basel); 2013 Oct; 5(4):1332-54. PubMed ID: 24202448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?
    Snow ET; Sykora P; Durham TR; Klein CB
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):557-64. PubMed ID: 15996700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of non-genotoxic carcinogens and importance of a weight of evidence approach.
    Hernández LG; van Steeg H; Luijten M; van Benthem J
    Mutat Res; 2009; 682(2-3):94-109. PubMed ID: 19631282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low doses and thresholds in genotoxicity: from theories to experiments.
    Zito R
    J Exp Clin Cancer Res; 2001 Sep; 20(3):315-25. PubMed ID: 11718209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-benzene hexachloride exerts hormesis in preneoplastic lesion formation of rat hepatocarcinogenesis with the possible role for hepatic detoxifying enzymes.
    Puatanachokchai R; Morimura K; Wanibuchi H; Oka M; Kinoshita A; Mitsuru F; Yamaguchi S; Funae Y; Fukushima S
    Cancer Lett; 2006 Aug; 240(1):102-13. PubMed ID: 16246485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of human carcinogens.
    Barrett JC; Shelby MD
    Prog Clin Biol Res; 1992; 374():415-34. PubMed ID: 1620716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Theory and practice of primary cancer prevention].
    Tompa A
    Magy Onkol; 2007; 51(1):7-21. PubMed ID: 17417671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of non-genotoxic carcinogenesis in rats using changes in gene expression following acute dosing.
    Nioi P; Pardo ID; Sherratt PJ; Snyder RD
    Chem Biol Interact; 2008 Apr; 172(3):206-15. PubMed ID: 18328469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do dose response thresholds exist for genotoxic alkylating agents?
    Jenkins GJ; Doak SH; Johnson GE; Quick E; Waters EM; Parry JM
    Mutagenesis; 2005 Nov; 20(6):389-98. PubMed ID: 16135536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of cancer and the dose-effect relationship: the carcinogenic effects of ionizing radiations].
    Tubiana M
    Cancer Radiother; 2009 Jul; 13(4):238-58. PubMed ID: 19539515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinogenic risks of dioxin: mechanistic considerations.
    Schwarz M; Appel KE
    Regul Toxicol Pharmacol; 2005 Oct; 43(1):19-34. PubMed ID: 16054739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion.
    Counts JL; Goodman JI
    Prog Clin Biol Res; 1995; 391():81-101. PubMed ID: 8532739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal.
    O'Brien J; Renwick AG; Constable A; Dybing E; Müller DJ; Schlatter J; Slob W; Tueting W; van Benthem J; Williams GM; Wolfreys A
    Food Chem Toxicol; 2006 Oct; 44(10):1613-35. PubMed ID: 16887251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive approach for integration of toxicity and cancer risk assessments.
    Butterworth BE; Bogdanffy MS
    Regul Toxicol Pharmacol; 1999 Feb; 29(1):23-36. PubMed ID: 10051416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic carcinogens: evaluation and risk assessment.
    Williams GM; Whysner J
    Exp Toxicol Pathol; 1996 Feb; 48(2-3):189-95. PubMed ID: 8672874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of arsenic genotoxicity for dose response of carcinogenic effects.
    Rudel R; Slayton TM; Beck BD
    Regul Toxicol Pharmacol; 1996 Apr; 23(2):87-105. PubMed ID: 8661328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging challenges in toxicopathology: carcinogenic threshold of phenobarbital and proof of arsenic carcinogenicity using rat medium-term bioassays for carcinogens.
    Fukushima S; Morimura K; Wanibuchi H; Kinoshita A; Salim EI
    Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):225-9. PubMed ID: 15993454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.